Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells
among persons with hemophilia.
4% and haemoglobin concentration <8 g/dl should have early initiation of ART since they are more likely to have a low CD4+ cell
count, whereas those presenting with pleuritic pain are less likely to have a low CD4+ count.
Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell
counts of > or =300/[mm.
He tested HIV-positive in 1993 (CDC Classification B3), and his CD4+ cell
count nadir was 121 cells/[mm.
Logistic regression analyses that corrected for risk factors such as CD4+ cell
count, age, race or ethnicity, and use of tobacco, alcohol or illicit drugs revealed that the risks of premature or very premature delivery and low or very low birth weight for women who had used any combined drug regimen were similar to those for women who had used monotherapy.
A secondary endpoint is the relationship between the number of antisense RNA-containing CD4+ cells
, the HIV-1 viral load and the CD4+ cell
count as measured monthly for six months.
The protocol has been modified to increase the proportion of engineered stem cells that engraft in the patient's bone marrow, thus increasing the progeny CD4+ cells
Effect of interleukin-2 on clinical outcomes in patients with CD4+ cell
count 50 to 299/[mm.
felis infection, which occurred in an HIV-positive man who, in spite of a very low CD4+ cell
count, successfully recovered with paromomycin treatment.
These data are extremely significant not only for their effectiveness in reducing virus and increasing CD4+ cell
levels, but also because these effects persisted throughout the year- long study," said Dr.
The enrollment of additional patients in Europe will allow us to generate important data on IR103's role in stabilizing CD4+ cell
counts in HIV drug-naive patients.
NASDAQ: ALBM) today announced the publication of a clinical trial in which patients who completed one year of treatment with the company's Thymosin alpha 1 drug plus AZT and alpha interferon had the greatest increase in CD4+ cell
counts when compared with patients who received three other treatment regimens.
The Phase I study that took place at UCSF demonstrated the safety of the procedure and showed that the engineered stem cells were able to survive long term in vivo and to produce a low number of CD4+ cell
progeny containing functioning antisense genes.
The analysis included data from 49 patients that completed the study, and showed that median absolute CD4+ cell
counts remained stable through week 28 in the patients that received three injections of the HIV-1 immunogen but declined in both the IFA and saline groups.
Final data from a 51 drug-naive patient Phase II Italian study of REMUNE(R), reported last year, showed that median absolute CD4+ cell
counts of patients that received 3 injections of the Company's first generation immunotherapy remained stable through week 28, while they declined in patients in the placebo groups.